NCT01025596View on ClinicalTrials.gov

Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

February 28, 2011

Study Completion Date

March 31, 2012

Conditions
Hepatitis C
Interventions
DRUG

Interleukin-7

4dose levels: 3, 10, 20 and 30µg/kg. 4 administrations, 1 per week

Trial Locations (7)

Unknown

Hopital Jean Verdier, Bondy

Beaujon Hospital, Clichy

Hopital Kremlin Bicêtre, Le Kremlin-Bicêtre

Hopital Civil, Strasbourg

Azienda Ospedaliero-Universitaria, Policlinico Sant'Orsola Malpighi, Bologna

San Raffaele Scientific Institute, Milan

University of Zurich, Zurich

Sponsors

Lead Sponsor

Cytheris SA
All Listed Sponsors
lead

Cytheris SA

INDUSTRY